TMDX logo

TransMedics Group, Inc. Stock Price

NasdaqGM:TMDX Community·US$3.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 175 Fair Values set on narratives written by author

TMDX Share Price Performance

US$90.85
-27.96 (-23.53%)
US$97.30
Fair Value
US$90.85
-27.96 (-23.53%)
6.6% undervalued intrinsic discount
US$97.30
Fair Value
Price US$90.85
AnalystConsensusTarget US$97.30
AnalystHighTarget US$142.00
AnalystLowTarget US$80.00

TMDX Community Narratives

·
Fair Value US$97.3 6.6% undervalued intrinsic discount

TMDX: Expanding Organ Donor Pool And Clinical Trials Will Shape Future Direction

3users have liked this narrative
0users have commented on this narrative
74users have followed this narrative
·
Fair Value US$142 36.0% undervalued intrinsic discount

Transplant Logistics Will Meet Demand From An Aging World

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
·
Fair Value US$80 13.6% overvalued intrinsic discount

Cost Pressures And Supply Risks Will Weaken Transplant Market Viability

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
US$97.3
6.6% undervalued intrinsic discount
Revenue
18.01% p.a.
Profit Margin
17.54%
Future PE
22.91x
Price in 2029
US$120.98
US$80
13.6% overvalued intrinsic discount
Revenue
17.21% p.a.
Profit Margin
13.17%
Future PE
27.02x
Price in 2029
US$101.14

Trending Discussion

No trending discussion available.

Updated Narratives

TMDX logo

TMDX: Transplant Procedure And Flight Network Expansion Will Drive Future Upside Potential

Fair Value: US$97.3 6.6% undervalued intrinsic discount
74 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
TMDX logo

TMDX: Rising Transplant And Flight Activity Will Drive Bullish 2026 Outlook

Fair Value: US$80 13.6% overvalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
TMDX logo

TMDX: Organ Platform Expansion And Clinical Adoption Will Drive Future Repricing

Fair Value: US$142 36.0% undervalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Outstanding track record and undervalued.

0 Risks
4 Rewards

TransMedics Group, Inc. Key Details

US$668.5m

Revenue

US$276.1m

Cost of Revenue

US$392.3m

Gross Profit

US$240.6m

Other Expenses

US$151.7m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
4.37
58.69%
22.69%
99.2%
View Full Analysis

About TMDX

Founded
1998
Employees
898
CEO
Waleed Hassanein
WebsiteView website
www.transmedics.com

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Recent TMDX News & Updates

Narrative Update Aug 08

TMDX: Transplant Procedure And Flight Network Expansion Will Drive Future Upside Potential

Analysts have reduced their average price target on TransMedics Group from about $112.89 to roughly $97.30. This change reflects updated views that balance mixed Q2 results, healthy transplant and flight activity trends, and differing opinions on long term competitive risks.

Recent updates

No updates